Seattle, Washington, United States The main department of described VC is located in the Seattle. The venture was found in North America in United States.
This organization was formed by Mitchell H. Gold.
The standard case for the fund is to invest in rounds with 2-3 partakers. The meaningful sponsors for the fund in investment in the same round are Frazier Healthcare Partners, OrbiMed.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 1 and less years to receive the investment from the fund. Among the most popular fund investment industries, there are Pharmaceutical, Health Care. Among the most popular portfolio startups of the fund, we may highlight Alpine Immune Sciences.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year. The high activity for fund was in 2016.
Related Funds
| Fund Name | Location |
| Alitheia Capital | Lagos, Lagos, Nigeria |
| Archipelago Next | Las Palmas, Las Palmas de Gran Canaria, Spain |
| Bank of Ireland Seed and Early Stage Equity fund | County Dublin, Dublin, Ireland |
| Datamat IS | - |
| GIG | - |
| Groupama Banque | France, Ile-de-France, Montreuil |
| GSR | China, Hong Kong, Hong Kong Island |
| James River Capital | Manakin Sabot, United States, Virginia |
| Milliways Ventures | California, Palo Alto, United States |
| Mingxiao Capital | - |
| MUUS | New York, New York, United States |
| Nexity | France, Ile-de-France, Paris |
| Ruichuan Chuangye | China, Shanghai |
| S.A.C Capital Associates | New York, New York, United States |
| Seen & Speed Ventures | - |
| SMBC Trust Bank | Japan, Tokyo |
| Theravance Biopharma | California, South San Francisco, United States |
| Trinad Capital | California, Los Angeles, United States |
| Wonky Ventures | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Mavupharma | $20M | 29 Nov 2017 | Washington, United States | ||
Alpine Immune Sciences | $48M | 13 Jun 2016 | Seattle, Washington, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Mavupharma | $20M | 29 Nov 2017 | Washington, United States | ||
Alpine Immune Sciences | $48M | 13 Jun 2016 | Seattle, Washington, United States |
